MATTHEW LAMCA: Open Payments
NPI 1346762325 · BUCKEYE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$948 in 31 payments from 14 companies in 2025. Trend: 2023 $1,220 · 2024 $1,613 · 2025 $948
Food & beverage: $948
| Company | Payments | Amount |
|---|---|---|
| Organon LLC | 4 | $191 |
| Janssen Biotech, Inc. | 4 | $187 |
| Incyte Corporation | 1 | $128 |
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
| Botanix SB Inc | 1 | $69 |
| Amgen Inc. | 4 | $63 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 3 | $49 |
| ABBVIE INC. | 2 | $43 |
| Lilly USA, LLC | 1 | $26 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $26 |
Products named: VTAMA, TREMFYA, Opzelura, DUPIXENT, SOFDRA, OTEZLA, JUBLIA, SKYRIZI.
Industry payments across AZ — which companies pay providers there.
